Louisiana State Employees Retirement System Invests $664,000 in Omnicell, Inc. $OMCL

Louisiana State Employees Retirement System purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the first quarter, HoldingsChannel.com reports. The institutional investor purchased 19,900 shares of the company’s stock, valued at approximately $664,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Dana Investment Advisors Inc. purchased a new position in shares of Omnicell in the 4th quarter valued at approximately $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Omnicell by 71.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock worth $6,343,000 after purchasing an additional 58,193 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after purchasing an additional 117,556 shares during the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of Omnicell during the fourth quarter worth $4,804,000. Finally, Dynamic Technology Lab Private Ltd lifted its holdings in shares of Omnicell by 345.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after purchasing an additional 24,738 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by insiders.

Omnicell Price Performance

OMCL stock traded down $0.80 during trading on Tuesday, reaching $44.44. 34,305 shares of the company were exchanged, compared to its average volume of 635,248. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. The stock’s 50 day moving average price is $41.92 and its 200 day moving average price is $41.52. Omnicell, Inc. has a 52-week low of $26.84 and a 52-week high of $55.00. The company has a market cap of $2.02 billion, a P/E ratio of 101.39, a PEG ratio of 1.11 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company’s quarterly revenue was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts predict that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on OMCL. Craig Hallum reissued a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Wells Fargo & Company raised their target price on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. UBS Group set a $60.00 price target on shares of Omnicell and gave the stock a “buy” rating in a research note on Friday, March 13th. KeyCorp increased their price target on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.